Hana Acquires Inex Marqibo; New Development Focus Is Adult & Elderly ALL
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Hana Biosciences initially will develop Marqibo for use in acute lymphoblastic leukemia following acquisition of the sphingosomal vincristine formulation from Inex
You may also be interested in...
Talon’s Marqibo Faces Commercial Challenges After FDA Approval
Talon is preparing to launch the leukemia drug on its own in the first quarter of 2013 but remains in talks with potential strategic partners. The company agreed to monitor whether clinical practices experience safety or technical problems while following the 26-step process for preparing the drug for administration.
Talon May Soon Have First Marqibo Approval In Its Grasp
Biotech formerly known as Hana Biosciences submits NDA for the nano-encapsulated vincristine for use as salvage in adults with Ph- ALL.
Phase II ALL a go for Hana Marqibo
Hana Biosciences has initiated a Phase II Marqibo (vincristine liposomal injection) trial for use in acute lymphoblastic leukemia after acquiring the formulation from Inex (1Pharmaceutical Approvals Monthly April 2006, p. 7). FDA issued a "not approvable" letter to Inex for Marqibo for treatment of relapsed aggressive non-Hodgkin's lymphoma in 2005. The company hopes to initiate a Phase III ALL trial by the end of 2006...